Seth A. Tasker J.D. serves as Senior Vice President, Chief Business Officer and Secretary of the Company. Mr. Tasker previously served as our Vice President, General Counsel and Secretary between July 2016 and December 2019, our Deputy General Counsel between March 2015 and July 2016, our Associate General Counsel between March 2013 and March 2015, our Assistant General Counsel between March 2010 and March 2013, and our Corporate Counsel between March 2008 and March 2010. Prior to joining Infinity, Mr. Tasker served in varying levels of responsibility in the legal function at Surface Logix, Inc., a privately held biopharmaceutical company, from 2001 to 2008. Mr. Tasker holds a B.S. in Microbiology from the University of Vermont, a J.D. from Suffolk University Law School, and an M.B.A. from Suffolk University Sawyer School of Management.
As the Senior Vice President、 Chief Business Officer and Secretary of Infinity Pharmaceuticals, the total compensation of Seth Tasker at Infinity Pharmaceuticals is 1,127,440$. There are 4 executives at Infinity Pharmaceuticals getting paid more, with Adelene Perkins having the highest compensation of 1,680,860$.
Seth Tasker is 41, he's been the Senior Vice President、 Chief Business Officer and Secretary of Infinity Pharmaceuticals since 2019. There are 17 older and no younger executives at Infinity Pharmaceuticals. The oldest executive at Infinity Pharmaceuticals Inc. is Anthony Evnin, 79, who is the Independent Director.
Seth's mailing address filed with the SEC is C/O INFINITY PHARMACEUTICALS, INC., 1100 MASSACHUSETTS AVENUE, FLOOR 4, CAMBRIDGE, MA, 02138.
Over the last 18 years, insiders at Infinity Pharmaceuticals have traded over 485,846,497$ worth of Infinity Pharmaceuticals stock and bought 22,639,120 units worth 175,155,554$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Partners L P/Ilbiotechnolog...、Medical Co L.P. Rosebay. On average, Infinity Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of 14,976$. The most recent stock trade was executed by Adelene Q Perkins on 8 September 2023, trading 768,133 units of INFI stock currently worth 15,363$.
the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business
Infinity Pharmaceuticals executives and other stock owners filed with the SEC include: